Group B streptococcus and preventive strategies in Europe
- A Berardi1,2,3,4,
- L Lugli1,2,3,4,
- C Rossi1,2,3,4,
- M S Morini1,2,3,4,
- F Vagnarelli1,2,3,4,
- F Ferrari1,2,3,4
- 1Unitè Operativa di Neonatologia, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy
- 2Unitè Operativa di Pediatria, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy
- 3Unitè Operativa di Pediatria, Ospedale Pierantoni, Forlì, Italy
- 4Unitè Operativa di Neonatologia, Azienda Ospedaliera S Maria Nuova, Reggio Emilia, Italy
- A Berardi, Unitè Operativa di Neonatologia, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy; berardi.alberto{at}policlinico.mo.it
We found Trijbels-Smeulders and coworkers epidemiology report very interesting.1 They studied early and late onset neonatal group B streptococcal (GBS) disease in the Netherlands before and after the introduction of guidelines for prevention. The best strategy in European countries is still a matter of debate and we need data which will allow reliable comparisons to be made between countries. In the USA the rate of early onset disease (EOD) has decreased markedly from 1.7/1000 to 0.34/1000 livebirths (70% reduction) after the adoption of guidelines and use of antibiotic prophylaxis.2 In contrast, the incidence of EOD is lower in the UK (0.48/1000 live …
